OR WAIT 15 SECS
Recipharm adds inhalation drug manufacturing capacity with the acquisition of Sanofi’s Holmes Chapel, UK site.
Contract development and manufacturing firm Recipharm announced on June 14, 2018 plans to expand its presence in the respiratory drug market with the acquisition of Sanofi’s Holmes Chapel manufacturing site in Cheshire, UK for £45 million.
The acquisition provides Recipharm with adds additional inhalation commercial drug product manufacturing capabilities, complementing services already offered by Recipharm’s inhalation development facility in the United States, the company reported in statement announcing the acquisition. Sanofi has also entered into a long-term supply agreement for the products currently manufactured at the facility.
The facility, which covers 125,000 square meters, manufactures metered dose inhalers and nasal sprays and develops dry-powder inhalation technologies. The 450 employees will transfer to Recipharm, the statement noted. The transaction is expected to close in the fourth quarter of 2018.
“Holmes Chapel brings Recipharm an ideal opportunity to accelerate its offering to customers with access to novel of respiratory products. As an already successful CMO with several clients, we look forward to introducing new contracts to Holmes Chapel by utilizing our growing franchise in development services. Treatments for asthma and chronic obstructive pulmonary disease (COPD) are growing at a fast rate, and we see many opportunities. The experienced management team and staff have already successfully attracted new customers, and we look forward to building on this from the well invested facility,” said Thomas Eldered, CEO of Recipharm in the statement.